{"entity":{"id":"nct05118776","kind":"trial","name":"Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM","aka":[],"tldr":"A phase 3 trial testing ASC40 in glioma & glioblastoma, active and no longer recruiting.","summary":"Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM is a phase 3 interventional study registered as NCT05118776, led by Ascletis Pharmaceuticals, and active but no longer recruiting on the registry. Official title: A Phase III Randomised, Double-blind, Placebo-controlled, Multi-centre Trial to Evaluate Safety and Efficacy pf ASC40 Tablets Combined With Bevacizumab in Subjects With Recurrent Glioblastoma. Planned enrolment is 136 participants (actual). The study started in 2022-01-21 and primary completion is expected in 2025-06. No results have been posted on ClinicalTrials.gov.","status":"active","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT05118776","url":"https://clinicaltrials.gov/study/NCT05118776"}],"tags":["ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["asc40"],"companies":["ascletis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05118776","phase":"3","setting":"A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Evaluate Safety and Efficacy pf ASC40 Tablets Combined With Bevacizumab in Subjects With Recurrent Glioblastoma","sponsor":"Ascletis Pharmaceuticals","started":"2022-01-21","startedType":"actual","enrolled":136,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05118776/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"drug":[{"id":"asc40","kind":"drug","name":"ASC40","route":"/drugs/asc40/"}],"company":[{"id":"ascletis","kind":"company","name":"Ascletis Pharma","route":"/companies/ascletis/"}]}}